How Biopharma & Medical Device Companies are Pivoting to Support the Boom in Telehealth During the COVID-19 Pandemic and Beyond

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Medical Device; Health Care; Biotech; Consulting; Consumer Products; Clinical Research; Laboratories; Medical


Companies Profiled:
AbbVie; Alkermes; Ascensia; AstraZeneca; BioDelivery Sciences International; Inc.; B.Braun; Canopy Growth; Catalyst Pharma; Daiichi Sankyo; DBV Tehcnologies; Dendreon Pharmaceuticals LLC; DiaSorin; EHOB; Inc; eNeura Therapeutics; Frankel Advisory Group LLC; Galderma; Greenwich Biosciences; Johnson & Johnson; Merck; Novartis; Panacea Biotec; Pfizer; Piramal Group; Rigel Pharmaceuticals; Sanofi; Santen; Sivantos Pte. Ltd.; Stgilesmedical London & Berlin; Sumitovant BioPharma; UCB Pharma; ViiV Healthcare; Zydus Cadila

Study Snapshot

Best Practices, LLC engaged 36 leaders from 32 biopharma and medical device organizations in this research through a benchmarking survey. Ninety percent of the participants serve at the director-level and above.

Key topics covered in this report include:

• Impact of Operational Services via Telehealth Channel
• Telehealth Service Channels
• Key Lessons Learned
• Telehealth Change Duration

• Telehealth channel attraction will continue its growth across all operational areas post COVID-19 pandemic: Patient Support and Medical Affairs will have prominent roles in patient education and clinical support, whereas Sales will be the first to try and offer services via telehealth channel. Health Outcomes plans to offer valuable tele-services in the clinical support space.

• Pharma plans to evolve delivery of outcomes studies (88%), support aids (76%), education & program support for providers and patients (>60%) over the telehealth channel. Currently, 60% of industry sales leaders provide targeted support through the tele-channel.

Sr. No.	Topic	Slide No.
I.	Overview	p. 3-5
	Universe of Learning	p. 4
	Key Insights	p. 5
II.	Impact of Operational Services via Telehealth Channel	p. 6-8
III.	Telehealth Service Channels	p. 9-17
IV.	Lessons Learned	p. 18-19
V.	Telehealth Change Duration	p. 20-22
VI.	Participant Demographics	p. 23-25
VII.	About Best Practices, LLC	p. 26

• Future prospects of various biopharma operational groups in offering valuable services in support of the rapidly emerging tele-health channel – Medical, Marketing, Market Research and Sales groups
• Future prospects of various biopharma operational groups in offering valuable services in support of the rapidly emerging tele-health channel – Health Outcomes, Managed Markets, Clinical Operations and Patient Support groups

• Medical Affairs services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
• Medical Affairs support for telehealth channel
• Sales services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
• Sales support for telehealth channel
• Market Research services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
• Adaptions of various functions
• Marketing services refitted or adjusted by benchmark companies to support healthcare services delivered over telehealth channels, in light of the COVID-19 pandemic
• New services piloted or in planning by benchmark companies to support a world where tele-medicine becomes an ongoing healthcare delivery channel, in light of the COVID-19 pandemic

• Lessons learned in each operational area related to telehealth delivery channel during COVID-19

• Benchmark groups’ planned approach to supporting telemedicine services after the global pandemic is ove